SYNCHRONIZING
THE POWER OF
INTRATUMORAL
IMMUNOTHERAPY
Syncromune™ is developing Syncrovax™, a next generation fixed-dose combination intratumoral immunotherapy platform
OUR
VISION
To Advance Fixed-Dose Combination Intratumoral Immunotherapy to Fight Cancer in a New Way
Large Unmet Need
Significant unmet global need for therapies that effectively and safely target metastatic cancers
Disruptive Research
Dedicated to developing a next generation therapy centered around intratumoral drugs with multiple active ingredients
Technology Platform
Fixed-dose combination drug candidates are being developed for several metastatic solid tumor cancers
A New Approach
Combination of lysis with intratumoral fixed-dose combination drugs to address the multiple mechanisms of immunosuppression
BRINGING HOPE TO METASTATIC CANCER PATIENTS
-
The body's immune system has the power to fight cancer.
-
Cancer evades the immune system with several defenses.
-
We are developing a next generation fixed-dose combination therapy to address the multiple mechanisms of immunosuppression
Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., …
We’re looking for people who want to change lives and share our passion for finding a cure. Join us in the fight against cancer.
Learn more about our plans to develop a scalable platform for long-term, sustained growth.
Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.